ViviCells International, Inc. (VCII)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ViviCells International, Inc. (VCII) with AI Score 50/100 (Hold). ViviCells International, Inc. operates as a stem cell preservation company. Formerly Tropical Beverage Inc. Market cap: 0, Sector: Utilities.
Last analyzed: Mar 16, 2026ViviCells International, Inc. (VCII) Utility Operations & Dividend Profile
ViviCells International, Inc., established in 1995 and based in Evanston, Illinois, focuses on stem cell preservation. Formerly Tropical Beverage Inc., the company transitioned in 2008. With a negative profit margin of -8.6% and a debt-to-equity ratio of 107.13, the company operates within the utilities-renewable sector.
Investment Thesis
Investing in ViviCells International, Inc. presents a speculative opportunity given its current financial metrics and limited publicly available information. The company's negative profit margin of -8.6% indicates it is not currently profitable, and its high beta of 45.79 suggests extreme volatility compared to the market. The debt-to-equity ratio of 107.13 signals a significant reliance on debt financing. A potential growth catalyst lies in expanding its stem cell preservation services to new markets or developing innovative preservation technologies. However, the lack of a dividend yield means investors are solely reliant on capital appreciation. The company's success hinges on its ability to achieve profitability and manage its debt effectively.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates a micro-cap or nano-cap company with limited market presence.
- Negative profit margin of -8.6% suggests the company is currently operating at a loss.
- Gross margin of 22.2% indicates the company retains a portion of revenue after accounting for the cost of goods sold, but this is insufficient to achieve profitability given current operating expenses.
- Debt-to-equity ratio of 107.13 suggests a high level of financial leverage, increasing financial risk.
- Beta of 45.79 indicates extremely high volatility relative to the overall market, suggesting a speculative investment.
Strengths
- Focus on a niche market (stem cell preservation).
- Potential for growth in the regenerative medicine field.
- Established presence since 1995.
- Strategic location in Evanston, Illinois.
Weaknesses
- Negative profit margin.
- High debt-to-equity ratio.
- Limited publicly available information.
- Small market capitalization.
Catalysts
- Upcoming: Potential partnerships with research institutions could drive increased demand for stem cell preservation services.
- Upcoming: Development of new stem cell preservation technologies could enhance the company's competitive advantage.
- Ongoing: Increasing awareness of regenerative medicine and personalized healthcare could drive long-term growth in the stem cell preservation market.
Risks
- Potential: Competition from established biotechnology companies with greater resources and expertise.
- Potential: Technological advancements rendering current preservation methods obsolete.
- Potential: Regulatory changes impacting stem cell research and preservation.
- Ongoing: The company's negative profit margin and high debt-to-equity ratio pose significant financial risks.
- Ongoing: Limited liquidity and the OTC Other listing status increase the volatility and risk of investing in VCII.
Growth Opportunities
- Expansion into New Geographic Markets: ViviCells International, Inc. can explore expanding its stem cell preservation services to new geographic markets, particularly in regions with growing biotechnology and healthcare sectors. This expansion could involve establishing new facilities or partnering with existing healthcare providers. The global stem cell market is projected to reach billions of dollars by 2030, presenting a significant opportunity for growth. Timeline: 2-3 years to establish initial operations in a new region.
- Development of Advanced Preservation Technologies: Investing in research and development to create more advanced and efficient stem cell preservation technologies could provide a competitive edge. This could involve exploring cryopreservation techniques, developing specialized storage solutions, or improving the viability of preserved stem cells. The market for advanced preservation technologies is driven by the increasing demand for high-quality stem cell samples for research and therapeutic applications. Timeline: Ongoing research and development efforts with potential breakthroughs within 1-2 years.
- Strategic Partnerships with Research Institutions: Forming strategic partnerships with research institutions and universities can provide access to a steady stream of stem cell samples for preservation. These partnerships can also facilitate collaborative research and development efforts, leading to the development of new preservation techniques and applications. The academic research market represents a significant opportunity for stem cell preservation services. Timeline: Initiate partnerships within the next 6-12 months.
- Offering Personalized Stem Cell Preservation Services: ViviCells International, Inc. can offer personalized stem cell preservation services to individuals seeking to preserve their stem cells for potential future medical treatments. This could involve collecting and preserving stem cells from various sources, such as umbilical cord blood or adult tissues. The market for personalized stem cell preservation is growing, driven by increasing awareness of the potential benefits of regenerative medicine. Timeline: Launch pilot program within the next year.
- Integration with Regenerative Medicine Clinics: Integrating stem cell preservation services with regenerative medicine clinics can create a synergistic business model. This could involve providing stem cell preservation services to patients undergoing regenerative medicine treatments, as well as utilizing preserved stem cells for research and development purposes. The regenerative medicine market is experiencing rapid growth, driven by advancements in stem cell therapies and tissue engineering. Timeline: Explore integration opportunities within the next 18-24 months.
Opportunities
- Expansion into new geographic markets.
- Development of advanced preservation technologies.
- Strategic partnerships with research institutions.
- Offering personalized stem cell preservation services.
Threats
- Competition from established biotechnology companies.
- Technological advancements rendering current preservation methods obsolete.
- Regulatory changes impacting stem cell research and preservation.
- Economic downturn affecting research funding and healthcare spending.
Competitive Advantages
- Specialized expertise in stem cell preservation techniques.
- Proprietary preservation technologies (if any).
- Established relationships with research institutions (if any).
About VCII
ViviCells International, Inc., originally incorporated in 1995 as Tropical Beverage Inc., underwent a significant transformation in May 2008 when it rebranded and shifted its focus to stem cell preservation. Based in Evanston, Illinois, the company operates within the utilities sector, specifically targeting the renewable energy segment due to the nature of stem cell preservation requiring specialized, sustainable energy solutions. The company's evolution from a beverage company to a stem cell preservation entity reflects a strategic pivot towards a niche market with potential long-term growth. ViviCells aims to provide advanced preservation services, potentially catering to both research institutions and individual clients seeking to preserve stem cells for future medical applications. While specific details on their preservation technologies and service offerings are limited, the company's core business revolves around maintaining the viability and integrity of stem cells through specialized processes and storage solutions. The company's current market position is not clearly defined due to limited information, but its focus on stem cell preservation suggests a targeted approach within the broader biotechnology and healthcare landscape.
What They Do
- Preserves stem cells using specialized techniques.
- Provides storage solutions for stem cell samples.
- Caters to research institutions requiring stem cell preservation.
- Potentially serves individual clients seeking stem cell preservation.
- Maintains the viability and integrity of stem cells.
- Operates within the biotechnology and healthcare sectors.
Business Model
- Generates revenue through stem cell preservation services.
- Potentially charges fees for storage and maintenance of stem cell samples.
- May offer customized preservation solutions for specific client needs.
Industry Context
ViviCells International, Inc. operates within the utilities sector, specifically in the renewable energy segment due to the power requirements of stem cell preservation. The global utilities market is undergoing a significant transformation, driven by the increasing demand for sustainable and renewable energy sources. The stem cell preservation market is a niche segment within the broader biotechnology and healthcare industries, driven by advancements in regenerative medicine and personalized healthcare. Competition in this niche is likely to include specialized biotech firms and research institutions with stem cell storage capabilities. The company's success depends on its ability to establish a competitive advantage through innovative preservation technologies and strategic partnerships.
Key Customers
- Research institutions conducting stem cell research.
- Biotechnology companies utilizing stem cells for therapeutic development.
- Individuals seeking to preserve their stem cells for future medical applications.
Financials
Chart & Info
ViviCells International, Inc. (VCII) stock price: Price data unavailable
Latest News
No recent news available for VCII.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VCII.
Price Targets
Wall Street price target analysis for VCII.
MoonshotScore
What does this score mean?
The MoonshotScore rates VCII's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
VCII OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ViviCells International, Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater regulatory scrutiny. Investing in OTC Other stocks carries significant risks due to the potential for fraud, lack of liquidity, and limited information available to investors. These stocks are generally considered highly speculative.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in VCII.
- Low liquidity can make it difficult to buy or sell shares.
- OTC Other stocks are subject to greater regulatory scrutiny and potential for fraud.
- The company's financial condition may be unstable.
- The company may not meet the listing requirements of higher-tier exchanges.
- Verify the company's registration and compliance with regulatory requirements.
- Obtain and review the company's financial statements (if available).
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and their track record.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any history of regulatory actions or legal disputes.
- Company has been in operation since 1995.
- Company headquarters are located in Evanston, Illinois.
- Company has a registered business name.
- Company changed its name and business focus in 2008, indicating a strategic shift.
What Investors Ask About ViviCells International, Inc. (VCII)
What does ViviCells International, Inc. do?
ViviCells International, Inc. operates as a stem cell preservation company, providing services to research institutions, biotechnology companies, and potentially individuals seeking to preserve stem cells for future medical applications. The company focuses on maintaining the viability and integrity of stem cells through specialized preservation techniques and storage solutions. Formerly Tropical Beverage Inc., the company transitioned to stem cell preservation in 2008, indicating a strategic shift towards the biotechnology and healthcare sectors. Their revenue model likely involves charging fees for preservation services and storage of stem cell samples.
What do analysts say about VCII stock?
There is no available analyst coverage for VCII stock, likely due to its OTC Other listing and small market capitalization. Given the lack of analyst opinions, potential investors must conduct their own thorough due diligence, carefully considering the company's financial condition, business model, and the risks associated with investing in OTC stocks. Key valuation metrics are difficult to assess due to limited financial disclosure. The company's growth prospects are uncertain and contingent on its ability to achieve profitability and manage its debt.
What are the main risks for VCII?
The main risks for ViviCells International, Inc. include its negative profit margin, high debt-to-equity ratio, and limited liquidity due to its OTC Other listing. Competition from established biotechnology companies with greater resources poses a significant threat. Technological advancements could render current preservation methods obsolete, requiring ongoing investment in research and development. Regulatory changes impacting stem cell research and preservation could also negatively affect the company's business. The lack of financial disclosure associated with OTC Other stocks further increases the risk for investors.
What are the key factors to evaluate for VCII?
ViviCells International, Inc. (VCII) currently holds an AI score of 50/100, indicating moderate score. Key strength: Focus on a niche market (stem cell preservation).. Primary risk to monitor: Potential: Competition from established biotechnology companies with greater resources and expertise.. This is not financial advice.
How frequently does VCII data refresh on this page?
VCII prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven VCII's recent stock price performance?
Recent price movement in ViviCells International, Inc. (VCII) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on a niche market (stem cell preservation).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider VCII overvalued or undervalued right now?
Determining whether ViviCells International, Inc. (VCII) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying VCII?
Before investing in ViviCells International, Inc. (VCII), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on ViviCells International, Inc. due to its OTC Other listing and lack of analyst coverage.
- Financial data is based on the most recent available information, which may be outdated.